VivoSeq
Oncology

Undifferentiated Carcinoma

4

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

Undifferentiated Carcinoma is an early-stage landscape with 4 programs across 3 companies. The most active players are Avyxa, Novartis, Sanofi. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Avyxa

1 program

Phase 2Novartis logo

Novartis

2 programs

ApprovedSanofi logo

Sanofi

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 22

Trametinib

Novartis

Docetaxel

Avyxa

Phase 31

Hydroxyurea

Theravia

Approved1

Dabrafenib

Novartis

Analysis

Trial Status

2

clinical trials

Completed1 · 50%
Unknown status1 · 50%

Clinical Trials

Trial Activity

NPC Study : TAX + CIS Neoadjuvant in Patients With Loco Regionally Advanced Undifferentiated Carcinoma of Nasopharyngeal Type (UCNT)
Completed·Sanofi logoSanofi·Phase 2·NCT00916097·66 enrolled
PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE.
Unknown status·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT00180973·520 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)